Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: A prospective, multicentre, observational study in Japan

Rheumatology (United Kingdom)

Volumn 54, Issue 4, 2014, Pages 683-691

  Takeuchi, Tsutomu ^a   Matsubara, Tsukasa ^b   Ohta, Shuji ^c   Mukai, Masaya ^d   Amano, Koichi ^e   Tohma, Shigeto ^f   Tanaka, Yoshiya ^g   Yamanaka, Hisashi ^h   Miyasaka, Nobuyuki ⁱ  

^a KEIO UNIVERSITY   (Japan)

^b Matsubara Mayflower Hospital   (Japan)

^c HITACHI LTD   (Japan)

^d SAPPORO CITY GENERAL HOSPITAL   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

^f SAGAMIHARA NATIONAL HOSPITAL   (Japan)

^g UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^h TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

ⁱ TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Abatacept; Biologic free remission; Observational study; Rheumatoid arthritis

Indexed keywords

ABATACEPT; C REACTIVE PROTEIN; METHOTREXATE; PLACEBO;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; BRONCHITIS; COMMON COLD; CONSTIPATION; CYSTITIS; DAS28; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HAQ DISABILITY INDEX; HUMAN; HUMEROSCAPULAR PERIARTHRITIS; JAPAN; JAPANESE (PEOPLE); LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 84926476207     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu338     Document Type: Article

References (29)

1. Ranheim EA, Kipps TJ. Elevated expression of CD80 (B7/BB1) and other accessory molecules on synovial fluid mononuclear cell subsets in rheumatoid arthritis. Arthritis Rheum 1994;37:1637-46.
2. Verwilghen J, Corrigall V, Pope RM, Rodrigues R, Panayi GS. Expression and function of CD5 and CD28 in patients with rheumatoid arthritis. Immunology 1993;80: 96-102.
3. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001;19:225-52.
4. Isaacs JD. Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future. Rheumatology 2008;47: 1461-8.
5. Moreland LW, Alten R, Van den Bosch F et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebocontrolled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002;46:1470-9.
6. Genant HK, Peterfy CG, Westhovens R et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2008;67:1084-9.
7. Takeuchi T, Matsubara T, Nitobe T et al. Phase II doseresponse study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. Mod Rheumatol 2013;23:226-35.
8. Kremer JM, Genant HK, Moreland LW et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-76.
9. Schiff M, Keiserman M, Codding C et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103.
10. Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23.
11. Bathon J, Robles M, Ximenes AC et al. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis 2011;70:1949-56.
12. Matsubara T, Yamana S, Tohma S et al. Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study. Mod Rheumatol 2013;23: 634-45.
13. Tanaka Y. Next stage of RA treatment: is TNF inhibitorfree remission a possible treatment goal? Ann Rheum Dis 2013;23:226-35.
14. Nishimoto N, Amano K, Hirabayashi Y et al. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol 2014;24:17-25.
15. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis 2007;66:407-9.
16. van der Heijde DM. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27: 261-3.
17. van der Heijde DM, van Leeuwen MA, van Riel PL et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992;35:26-34.
18. Vastesaeger N, Xu S, Aletaha D, St Clair EW, Smolen JS. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology 2009; 48:1114-21.
19. Smolen JS, van der Heijde DM, Keystone EC et al. Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate. Ann Rheum Dis 2013;72: 1156-62.
20. Kameda H, Kanbe K, Sato E et al. A merged presentation of clinical and radiographic data using probability plots in a clinical trial, the JESMR study. Ann Rheum Dis 2013;72: 310-2.
21. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
22. Li NL, Zhang DQ, Zhou KY et al. Isolation and characteristics of autoreactive T cells specific to aggrecan G1 domain from rheumatoid arthritis patients. Cell Res 2000; 10:39-49.
23. Klimiuk PA, Yang H, Goronzy JJ, Weyand CM. Production of cytokines and metalloproteinases in rheumatoid synovitis is T cell dependent. Clin Immunol 1999;90:65-78.
24. Smolen JS, Aletaha D, Bijlsma JW et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
25. Tanaka Y, Takeuchi T, Mimori T et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010;69: 1286-91.
26. Nawata M, Saito K, Nakayamada S, Tanaka Y. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol 2008;18: 460-4.
27. Kavanaugh A, Fleischmann RM, Emery P et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72: 64-71.
28. Harigai M, Takeuchi T, Tanaka Y et al. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Mod Rheumatol 2012; 22:814-22.
29. Emery P, Durez P, Dougados M et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 2010;69:510-6.